In conclusion, ZDQ-0620 was identified as being a PI3K target inhibitor, and displayed excellent anti-CRC activity, including the inhibition of cell proliferation, migration, invasion, protein synthesis, and angiogenesis, via the blocking of the PI3K/AKT/mTOR signaling pathway both in vitro and in vivo. Here, AKT1 is linked to colorectal carcinoma.